Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration
about
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationPlacebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysisAdjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomesReporting bias in medical research - a narrative reviewFalse hopes, unwarranted fears: the trouble with medical news storiesOn deciding to have a lobotomy: either lobotomies were justified or decisions under risk should not always seek to maximise expected utilityAre psychiatrists an endangered species? Observations on internal and external challenges to the professionDensity and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behaviorVortioxetine for depression in adultsOmega-3 fatty acids for depression in adultsAntidepressant treatment for postnatal depressionAlprazolam for depressionNon-specialist health worker interventions for the care of mental, neurological and substance-abuse disorders in low- and middle-income countriesAmitriptyline versus placebo for major depressive disorderNewer generation antidepressants for depressive disorders in children and adolescentsAmitriptyline versus placebo for major depressive disorderAntidepressants versus placebo for depression in primary careAcupuncture for depressionInterventions for treating depression after strokeThe effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect sizeEffectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?Which placebo to cure depression? A thought-provoking network meta-analysisAntidepressant drug effects and depression severity: a patient-level meta-analysisBenefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxineDecynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depressionReboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trialsEffectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug AdministrationA double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorderThe bright side of being blue: depression as an adaptation for analyzing complex problemsEfficacy of antidepressantsUnfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacyMelanin-Concentrating Hormone (MCH): Role in REM Sleep and DepressionOmega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviorsBenefits of a working memory training program for inattention in daily life: a systematic review and meta-analysisEnhancing placebo effects: insights from social psychologyThe genetics of major depressionThe 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouseIs there an excess of significant findings in published studies of psychotherapy for depression?Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date
P2860
Q21092360-9869F667-C115-4F82-B1C4-D9F09A629AC4Q21143851-F3195657-82A2-4A54-8E76-58FE130095E7Q21144599-53059B0F-8CA4-4EEE-B2EA-A33401EE02FEQ21203744-56425C93-20B9-4163-AF85-3561A8E64B52Q21563407-A648C19A-8DD3-4CA0-954C-A88EBBDD1841Q22252623-C0540268-C972-4E30-A91E-C35F88534A6CQ22252897-51A39511-DFCF-4BBE-9511-17A1DFD45CE7Q23913111-B42C051A-724C-4AD5-B2C1-2F73C53392BEQ24186313-E47E582C-4027-48B4-A86A-9DE24A10A4EDQ24187951-56717FD7-39DB-4A34-8727-D0E27A0913F4Q24193660-AE744928-0B60-4EEB-A244-82E3AB888A1FQ24201994-3CCD3B4B-EEAF-4C16-A54A-C015E3F58BF8Q24202405-1F48DCBC-1E4B-468D-84B3-F22F89A777CAQ24202486-F9D446F3-9CE0-4635-86F8-ACAFA307CCC3Q24202873-6A8D988D-540D-4C98-BD1B-197F26DB79E5Q24235000-6020E9B8-B939-44E1-B24B-C8232BC782D1Q24239979-56FB6E62-51F4-451F-986E-B6C99696F06AQ24240738-7101DD9B-1623-4785-BCBF-E90CDF720ADFQ24240748-45143CEC-7C42-42BC-B652-F9314CD2E830Q24273208-821FF5E3-28AB-4195-A206-3AF082DFA9CBQ24288917-D3B0681F-CBB7-423A-9A8E-95077E6FFAE5Q24288940-9D9F69FC-A1FD-4690-8326-8DD4835C0D63Q24598580-031A4EE6-F13D-4391-9561-6C1CCFE9C8FFQ24607720-B0E547CB-54A8-477C-8512-9051D7D8523FQ24611123-552DD1CA-AF64-42AD-AA3D-93E95340A0C3Q24632255-A4FF51C6-90AB-4D92-AFC9-A886A51E4770Q24633044-3B140AF5-C53F-4669-B3D5-96876EE788BDQ24634050-D3241714-403E-4CCD-A12A-0ADAC61A9CC3Q24645463-3D5891AE-1796-4B39-AC22-51F98A149E55Q24656010-30DEB49E-7B01-4664-881D-16A6305B8FEEQ24658095-FA3BF9FE-F4B0-4B71-954A-D2FA5F80CA1AQ26770777-5CB356F4-616F-4BFB-937E-6A4246C4DE7FQ26822591-A27A80CE-9EE0-4793-8874-4B30DEF02C1EQ26827341-528505F1-400A-4D9A-B946-AC54CADE9953Q26829966-3D6E9E06-AAED-434E-8FF5-2F00003DB30FQ26830784-6E520FA3-8963-471D-9D86-688BD38B82A4Q26849351-08EBFB52-6B74-4F2A-956E-A791FCBC747AQ26991727-0C046AA0-68CF-4221-BE6B-EFF776320836Q26996411-4B5DD42B-DA43-47E8-BEAD-B6D63190AF8BQ27004490-B128683E-EC23-4526-B9CE-4C8723321B33
P2860
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Initial severity and antidepre ...... e Food and Drug Administration
@ast
Initial severity and antidepre ...... e Food and Drug Administration
@en
Initial severity and antidepre ...... e Food and Drug Administration
@en-gb
Initial severity and antidepre ...... e Food and Drug Administration
@nl
type
label
Initial severity and antidepre ...... e Food and Drug Administration
@ast
Initial severity and antidepre ...... e Food and Drug Administration
@en
Initial severity and antidepre ...... e Food and Drug Administration
@en-gb
Initial severity and antidepre ...... e Food and Drug Administration
@nl
altLabel
Initial Severity and Antidepre ...... e Food and Drug Administration
@en
prefLabel
Initial severity and antidepre ...... e Food and Drug Administration
@ast
Initial severity and antidepre ...... e Food and Drug Administration
@en
Initial severity and antidepre ...... e Food and Drug Administration
@en-gb
Initial severity and antidepre ...... e Food and Drug Administration
@nl
P2093
P2860
P3181
P1433
P1476
Initial severity and antidepre ...... e Food and Drug Administration
@en
P2093
Alan Scoboria
Blair T Johnson
Brett J Deacon
Tania B Huedo-Medina
Thomas J Moore
P2860
P3181
P356
10.1371/JOURNAL.PMED.0050045
P407
P577
2008-02-01T00:00:00Z